LifeArc CEO Sam Barrell on Turning Drug Discovery into Real Benefits for Patients

Drug discovery and patient impact, Digimart Global: In an interview with News-Medical, Dr Sam Barrell CBE, chief executive of LifeArc, a self-funded medical research organisation, discussed the changing landscape of drug discovery and the difficulty of turning scientific breakthroughs into improvements in patients’ lives. Barrell, who trained as a doctor and later moved into NHS leadership and major research organisations, said progress should be judged by whether it reaches the people who need it.

Barrell said scientific momentum must be measured in human terms, with a new platform, target or dataset mattering only if it gives a patient an answer, more time, a better treatment or hope. She said the drug discovery community can keep that connection by involving patients early, designing translation and access into programmes from the start, and bringing researchers, clinicians, regulators, funders and industry together around a shared patient need.

The interview identified rare diseases, neurodegenerative conditions, childhood cancers and drug-resistant infections as areas where the greatest unmet needs remain, often because biology is complex, patient populations are small, incentives are weak or delivery systems are fragmented. Barrell said rare disease research faces challenges including geographically dispersed patients, fragmented data, limited specialist capacity and difficult commercial models, and called for pathways designed specifically for rare diseases, including earlier diagnosis, sustainable registries, responsible data sharing and platform trials.

According to Barrell, LifeArc conducts its own science as well as supporting researchers and partners to help promising ideas progress. She said promising research can stall when the patient population or clinical pathway is poorly understood, evidence is not aligned with regulatory needs, manufacturing cannot scale, funding falls between stages, or there is no clear route to adoption.

She said LifeArc aims to combine scientific and translational expertise, funding and partnership-building to help programmes cross those gaps.

Barrell also pointed to emerging approaches, including genomics, AI, precision medicine, gene editing, RNA medicines and cell therapies, while noting that it is not yet known which advances will make the greatest difference to patients over the next 10 to 20 years. Her advice to the next generation of scientists was to remain ambitious while keeping the patient in view, and to recognise that a failed route does not mean failed science.

Callum Fletcher

Callum Fletcher covers international news, Australian sports, entertainment, and cultural developments. His reporting focuses on major global events and trending stories relevant to audiences throughout Australia.
Copy Profile

Leave a Reply

Your email address will not be published. Required fields are marked *

Sports

Explore Digimart Global